Version 1
: Received: 3 April 2024 / Approved: 4 April 2024 / Online: 4 April 2024 (08:10:30 CEST)
How to cite:
Riccio, G.; Neto, J.; Berenguer, C. V.; Ornelas, C. P.; Greco, V.; Pereira, J.; Perestrelo, R.; Câmara, J. S. Evaluation of the Potential of Urinary Volatilomic Patterns of COVID-19 Patients Infected With SARS-CoV-2 for Disease Diagnosis. An Exploratory Study. Preprints2024, 2024040355. https://doi.org/10.20944/preprints202404.0355.v1
Riccio, G.; Neto, J.; Berenguer, C. V.; Ornelas, C. P.; Greco, V.; Pereira, J.; Perestrelo, R.; Câmara, J. S. Evaluation of the Potential of Urinary Volatilomic Patterns of COVID-19 Patients Infected With SARS-CoV-2 for Disease Diagnosis. An Exploratory Study. Preprints 2024, 2024040355. https://doi.org/10.20944/preprints202404.0355.v1
Riccio, G.; Neto, J.; Berenguer, C. V.; Ornelas, C. P.; Greco, V.; Pereira, J.; Perestrelo, R.; Câmara, J. S. Evaluation of the Potential of Urinary Volatilomic Patterns of COVID-19 Patients Infected With SARS-CoV-2 for Disease Diagnosis. An Exploratory Study. Preprints2024, 2024040355. https://doi.org/10.20944/preprints202404.0355.v1
APA Style
Riccio, G., Neto, J., Berenguer, C. V., Ornelas, C. P., Greco, V., Pereira, J., Perestrelo, R., & Câmara, J. S. (2024). Evaluation of the Potential of Urinary Volatilomic Patterns of COVID-19 Patients Infected With SARS-CoV-2 for Disease Diagnosis. An Exploratory Study. Preprints. https://doi.org/10.20944/preprints202404.0355.v1
Chicago/Turabian Style
Riccio, G., Rosa Perestrelo and José S. Câmara. 2024 "Evaluation of the Potential of Urinary Volatilomic Patterns of COVID-19 Patients Infected With SARS-CoV-2 for Disease Diagnosis. An Exploratory Study" Preprints. https://doi.org/10.20944/preprints202404.0355.v1
Abstract
To assess if SARS-CoV-2 infection induces changes in the urinary volatilomic fingerprint able to be used in the non-invasive COVID-19 diagnosis and management, urine samples of SARS-CoV-2 infected patients (62), recovered COVID-19 patients (30), and non-infected individuals (41) were analysed using solid-phase microextraction technique in headspace mode, combined with gas chromatography hyphenated with mass spectrometry (HS-SPME/GC-MS). In total, 101 volatile organic metabolites (VOMs) from 13 chemical families were identified, being terpenes, phenolic compounds, norisoprenoids, and ketones the most represented groups. Overall, a decrease in the levels of terpenes and phenolic compounds was observed in the control group, whereas norisoprenoids and ketones showed a significant increase. In turn, a remarkable increase was noticed in norisoprenoids and ketones and a milder increase in alcohols, furanic, and sulfur compounds in the recovery group than in the COVID-19 group. Multivariate statistical analysis identified sets of VOMs with the potential to constitute volatile signatures for COVID-19 development and progression. These signatures are composed of D-carvone, 3-methoxy-5-(trifluoromethyl)aniline (MTA), 1,1,6-trimethyl-dihydronaphthalene (TDN), 2-heptanone, and 2,5,5,8a-tetramethyl-1,2,3,5,6,7,8,8-octahydro-1-naphthalenyl ester acetate (TONEA) for COVID-19 infection and nonanoic acid, α-terpinene, β-damascenone, α-isophorone, and trans-furan linalool for patients recovering from the disease. This study provides evidence that changes in the urinary volatilomic profile triggered by SARS-CoV-2 infection constitute a promising and valuable screening and/or diagnostic and management tool for COVID-19 in clinical environment.
Chemistry and Materials Science, Medicinal Chemistry
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.